210 related articles for article (PubMed ID: 28193167)
1. Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn's disease.
Lahat A; Kopylov U; Neuman S; Levhar N; Yablecovitch D; Avidan B; Weiss B; Ben-Horin S; Eliakim R;
BMC Gastroenterol; 2017 Feb; 17(1):27. PubMed ID: 28193167
[TBL] [Abstract][Full Text] [Related]
2. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
3. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
[TBL] [Abstract][Full Text] [Related]
4. Biochemical markers and MR imaging findings as predictors of crohn disease activity in patients scanned by contrast-enhanced MR enterography.
Quaia E; Cabibbo B; Sozzi M; Gennari AG; Pontello M; Degrassi F; Cova MA
Acad Radiol; 2014 Oct; 21(10):1225-32. PubMed ID: 24998692
[TBL] [Abstract][Full Text] [Related]
5. Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease.
Höög CM; Bark LÅ; Broström O; Sjöqvist U
Scand J Gastroenterol; 2014 Sep; 49(9):1084-90. PubMed ID: 24853318
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching.
Parente F; Molteni P; Bollani S; Maconi G; Vago L; Duca PG; Rembacken B; Axon AT; Bianchi Porro G
Scand J Gastroenterol; 1997 Nov; 32(11):1140-6. PubMed ID: 9399396
[TBL] [Abstract][Full Text] [Related]
7. Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out.
Bojarski C; Epple HJ; Kirstein FW; Fromm M; Bisson S; Riecken EO; Schulzke JD
Z Gastroenterol; 2000 Mar; 38(3):211-9. PubMed ID: 10768243
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis.
Tan WC; Hogan J; Purkayastha SK; Lombard M; Krasner N
Int J Clin Pract; 1997 Jun; 51(4):214-6. PubMed ID: 9287260
[TBL] [Abstract][Full Text] [Related]
9. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study.
Greener T; Klang E; Yablecovitch D; Lahat A; Neuman S; Levhar N; Avidan B; Yanai H; Dotan I; Chowers Y; Weiss B; Saibil F; Amitai MM; Ben-Horin S; Kopylov U; Eliakim R;
J Crohns Colitis; 2016 May; 10(5):525-31. PubMed ID: 26748404
[TBL] [Abstract][Full Text] [Related]
11. Protein microarray analysis for detection of serum anti-Helicobacter pylori antibodies after eradication therapy: a clinical follow-up.
Cui M; Wei H; Mu F; Yi G; Fu Y; Yue L
Hepatogastroenterology; 2015; 62(138):503-6. PubMed ID: 25916090
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of upper gastrointestinal lesions and Helicobacter pylori infection in Crohn's disease.
D'Incà R; Sturniolo G; Cassaro M; di Pace C; Longo G; Callegari I; Rugge M
Dig Dis Sci; 1998 May; 43(5):988-92. PubMed ID: 9590412
[TBL] [Abstract][Full Text] [Related]
13. Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin.
Bickelhaupt S; Pazahr S; Chuck N; Blume I; Froehlich JM; Cattin R; Raible S; Bouquet H; Bill U; Rogler G; Frei P; Boss A; Patak MA
Neurogastroenterol Motil; 2013 Jun; 25(6):467-73. PubMed ID: 23495824
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of Helicobacter pylori infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population.
Khor CJ; Fock KM; Ng TM; Teo EK; Sim CS; Tan AL; Ng A
Singapore Med J; 2000 Aug; 41(8):382-6. PubMed ID: 11256345
[TBL] [Abstract][Full Text] [Related]
15. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease.
Eder P; Stawczyk-Eder K; Łykowska-Szuber L; Krela-Kaźmierczak I; Klimczak K; Szymczak A; Szachta P; Linke K
Pol Arch Med Wewn; 2014; 124(1-2):51-7. PubMed ID: 24424551
[TBL] [Abstract][Full Text] [Related]
16. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
17. Impact of disease location on fecal calprotectin levels in Crohn's disease.
Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
[TBL] [Abstract][Full Text] [Related]
18. Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?
Jovanovic IR; Milosavjevic TN; Jankovic GP; Micev MM; Dugalic PD; Saranovic D; Ugljesic MM; Popovic DV; Bulajic MM
Med Sci Monit; 2001; 7(1):137-41. PubMed ID: 11208510
[TBL] [Abstract][Full Text] [Related]
19. [New ultrashort scheme for helicobacter pylori infection eradication using tetracyline, furazolidone and colloidal bismuth subcitrate in dyspeptic patients with or without peptic ulceration in the National Hospital Cayetano Heredia].
Araujo Castillo R; Pinto Valdivia JL; Ramírez D; Cok García J; Bussalleu Rivera A
Rev Gastroenterol Peru; 2005; 25(1):23-41. PubMed ID: 15818420
[TBL] [Abstract][Full Text] [Related]
20. Helicobacter pylori reinfection rate 3 years after successful eradication.
Zendehdel N; Nasseri-Moghaddam S; Malekzadeh R; Massarrat S; Sotoudeh M; Siavoshi F
J Gastroenterol Hepatol; 2005 Mar; 20(3):401-4. PubMed ID: 15740483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
